Lung, Phase III
A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer
Volunteers
Health Professionals
What is the purpose of this trial?
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Andrea Brennan, PA
- Armand Russo, MD
- Benjamin Y. Lu, MD, PhD
- Clarice Grens, APRN
- Elizabeth Gaa, APRN
- Emily Duffield, APRN
- Frederick Wilson, MD, PhD
- Harold Tara Jr, MD
- John Glendening, PA
- Marianne Davies, NP, DNP, MSN, APRN, BSN
- Michael Cohenuram, MD
- Roy S. Herbst, MD, PhD
- Sarah Goldberg, MD, MPH
- Scott Gettinger, MD
- So Yeon Kim, MD
- Yifei Zhang, MD
- Last Updated04/08/2026
- Study IRB#2000041311